1
|
Blanchard T, Hoummady S, Roche M, Banuls D, Bynens A, Meunier M, Djerene M, Dos Santos N, Tissaoui E, Rouch-Buck P, Fantinati M, Priymenko N. Prevalence and factors associated with overweight and obesity in dogs presenting to French university veterinary teaching hospitals during the COVID-19 pandemic. Top Companion Anim Med 2024; 60:100875. [PMID: 38631428 DOI: 10.1016/j.tcam.2024.100875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Revised: 02/20/2024] [Accepted: 04/11/2024] [Indexed: 04/19/2024]
Abstract
Pet obesity is still a major health issue, which is considered an epidemic by some researchers. Prevention is one of the cornerstones of veterinary care, emphasizing the importance of proactive measures. Human lifestyle was affected during the COVID-19 pandemic, resulting in an increased overweight prevalence in the population. The prevalence of overweight and obesity in dogs during this period has been poorly explored. This study's objectives were to assess the percentage of the French dog population with overweight and obesity, compare the results with a study conducted before the COVID-19 pandemic, and investigate any potential changes in the risk factors. The study collected data through a survey completed by dog owners during their pets' vaccination visits at university veterinary hospitals of Maisons-Alfort (Paris) and Toulouse, in France, between 2020 and 2022. The veterinarian recorded the dog's weight and the body condition score using a 9-point scale. The study included a total of 309 dogs. Of these, 1.6 % were underweight, 63.1 % had an ideal body condition, and 35.3 % were overweight, including 2.3 % of all dogs classified as obese. During the pandemic, French dog diets shifted towards increased commercial food consumption and twice-daily feedings compared to a 2003 study. Factors positively associated with overweight were being female (OR = 3.55; 95 % CI: 1.65-8.01; P=0.002), being senior (OR=4.91; 95 % CI: 2.07-12.2; P<0.001) or geriatric (OR=5.81; 95 % CI: 2.04-17.0; P=0.001) and having an owner underestimating dog's body condition (OR=74.1; 95 % CI: 29.8-215; P<0.001). Recognizing the impact of owner perception enables early intervention strategies, such as educating owners during consultations and conducting teaching sessions at the clinic. This proactive approach could contribute to improved health outcomes and help prevent the onset of obesity-related issues in dogs. The new trends in dogs' diets may have global relevance due to the pandemic's widespread impact. Although no immediate impact on overweight is evident, ongoing research is crucial to understand the pandemic's long-term effects.
Collapse
Affiliation(s)
- T Blanchard
- Ecole Nationale Vétérinaire de Toulouse ENVT, Toulouse, France.
| | - S Hoummady
- Ecole Nationale Vétérinaire d'Alfort ENVA, Maisons-Alfort, France
| | - M Roche
- Ecole Nationale Vétérinaire de Toulouse ENVT, Toulouse, France
| | - D Banuls
- Ecole Nationale Vétérinaire de Toulouse ENVT, Toulouse, France
| | - A Bynens
- Chats, Oiseaux et autres animaux familiers, Fédération des Fabricants d'Aliments pour Chiens, FACCO, Paris, France
| | - M Meunier
- Hill's Pet Nutrition France, Sophia Antipolis, France
| | - M Djerene
- Ecole Nationale Vétérinaire d'Alfort ENVA, Maisons-Alfort, France
| | - N Dos Santos
- Ecole Nationale Vétérinaire d'Alfort ENVA, Maisons-Alfort, France
| | - E Tissaoui
- Ecole Nationale Vétérinaire d'Alfort ENVA, Maisons-Alfort, France
| | - P Rouch-Buck
- Ecole Nationale Vétérinaire de Toulouse ENVT, Toulouse, France
| | - M Fantinati
- Hill's Pet Nutrition France, Sophia Antipolis, France
| | - N Priymenko
- Ecole Nationale Vétérinaire de Toulouse ENVT, Toulouse, France; INRAE, ENVT, TOXALIM, Université de Toulouse, Toulouse, France
| |
Collapse
|
2
|
Bernat M, Boyer A, Roche M, Richard C, Bouvet L, Remacle A, Antonini F, Poirier M, Pastene B, Hammad E, Fond G, Bruder N, Leone M, Zieleskiewicz L. Reducing the carbon footprint of general anaesthesia: a comparison of total intravenous anaesthesia vs. a mixed anaesthetic strategy in 47,157 adult patients. Anaesthesia 2024; 79:309-317. [PMID: 38205529 DOI: 10.1111/anae.16221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/14/2023] [Indexed: 01/12/2024]
Abstract
Global warming is a major public health concern. Volatile anaesthetics are greenhouse gases that increase the carbon footprint of healthcare. Modelling studies indicate that total intravenous anaesthesia is less carbon intensive than volatile anaesthesia, with equivalent quality of care. In this observational study, we aimed to apply the findings of previous modelling studies to compare the carbon footprint per general anaesthetic of an exclusive TIVA strategy vs. a mixed TIVA-volatile strategy. This comparative retrospective study was conducted over 2 years in two French hospitals, one using total intravenous anaesthesia only and one using a mixed strategy including both intravenous and inhalation anaesthetic techniques. Based on pharmacy procurement records, the quantity of anaesthetic sedative drugs was converted to carbon dioxide equivalents. The primary outcome was the difference in carbon footprint of hypnotic drugs per intervention between the two strategies. From 1 January 2021 to 31 December 2022, 25,137 patients received general anaesthesia in the hospital using the total intravenous anaesthesia strategy and 22,020 in the hospital using the mixed strategy. The carbon dioxide equivalent footprint of hypnotic drugs per intervention in the hospital using the total intravenous anaesthesia strategy was 20 times lower than in the hospital using the mixed strategy (emissions of 2.42 kg vs. 48.85 kg carbon dioxide equivalent per intervention, respectively). The total intravenous anaesthesia strategy significantly reduces the carbon footprint of hypnotic drugs in general anaesthesia in adult patients compared with a mixed strategy. Further research is warranted to assess the risk-benefit ratio of the widespread adoption of total intravenous anaesthesia.
Collapse
Affiliation(s)
- M Bernat
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - A Boyer
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - M Roche
- Pharmacy Department, Service Central des Opérations Pharmaceutiques, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - C Richard
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - L Bouvet
- Department of Anesthesia and Critical Care, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France
| | - A Remacle
- Departement of Medical Information, Hôpital Nord, Marseille, France
| | - F Antonini
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - M Poirier
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - B Pastene
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - E Hammad
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - G Fond
- CEReSS-Health Service Research and Quality of Life Center, Aix-Marseille University, Marseille, France
| | - N Bruder
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - M Leone
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| | - L Zieleskiewicz
- Department of Anaesthesia and Intensive Care Medicine, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| |
Collapse
|
3
|
Wallace N, Murphy G, Roche M, Rock K. Comparison of Four Software Packages for Automated Contouring. Int J Radiat Oncol Biol Phys 2023; 117:e731-e732. [PMID: 37786128 DOI: 10.1016/j.ijrobp.2023.06.2252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) We are an academic radiation oncology center and treat 1500-2000 patients annually. The majority of target volume definition and organ at risk (OAR) contouring is performed by radiation oncologists (RO) and is estimated to require 10-15 hours per week for each RO. Artificial intelligence (AI) solutions for contouring are a possible method of reducing the time required. Several packages are commercially available. The purpose of this exercise was to evaluate 4 packages to identify one which would meet our department's need. The primary objective was to calculate the potential time savings associated with each of the 4 packages. The second objective was to perform a qualitative evaluation and comparison. MATERIALS/METHODS Approval from the hospital's Research Ethics Committee was obtained. CT Simulation datasets for 15 patients were anonymized for use as test cases for AI contouring. This included 5 datasets from each of 3 sites - head and neck (H+N), breast/thorax, and prostate/pelvis. 4 potential vendors provided access to their product for automated contouring of OARs +/- target volumes of each of the 15 datasets. Analysis was as follows: 1. One RO used a stopwatch to assess the time taken for them to contour each of the OARs +/- targets on each dataset 2. The AI contours from each of the vendors for each of the datasets was reviewed. 3. The time taken to correct each auto-contoured organ to make it clinically useful was timed. These were summed to give a time for each vendor for each dataset. 4. The time saving was calculated by subtracting the result of step (3) from step (1) 5. For the purpose of qualitative assessment, 2 ROs reviewed each dataset and assigned an objective score of 1-5 to each auto-contoured organ (e.g., 5 = no, or almost no, edits required; clinically useful as is) 6. The scores for each organ in each of the 15 datasets were averaged to give a mean value for the software package. RESULTS Baseline contouring time was 32.8 minutes for H+N, 23.0 minutes for breast/thorax, and 64.8 minutes for prostate/pelvis. One package was removed from consideration after assessment of H+N only as it was deemed to be of insufficient standard to be of clinical use. The average time saving for each of the remaining 3 software packages ranged were 15.7, 17.9, and 12.8 minutes for H+N, 3.1, 13.1, and 11.0 minutes for breast/thorax, and 32.6, 35.2, and 36.2 minutes for prostate/pelvis. Percentage time savings ranged from 39-55% for H+N, 13-57% for breast/thorax, and 50-56% for prostate/pelvis. The overall qualitative assessments on a 5-point scale were 3.5, 4.0, and 3.6. CONCLUSION The AI contouring solutions were associated with meaningful savings in the time taken to contour. The introduction of one of these products into clinical practice within our department will permit ROs to focus more of their time on other clinical activities.
Collapse
Affiliation(s)
- N Wallace
- St.Luke's Radiation Oncology Network, Dublin, Ireland
| | - G Murphy
- Cork University Hospital, Cork, Ireland
| | - M Roche
- Cork University Hospital, Cork, Ireland
| | - K Rock
- Cork University Hospital, Cork, Ireland; University College Cork, Cork, Ireland
| |
Collapse
|
4
|
Wallace N, Murphy G, Roche M, Rock K. Comparative Evaluation of Four Software Packages for Automated Contouring. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
5
|
Imfeld D, Klaassens E, Claypool J, Roche M, Sfriso R. 566 Modulation of cutibacterium acnes phylotypes after treatment with epilobium fleischeri extract. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Vacheron CH, Bitker L, Thiolliére F, Subtil F, Abraham P, Collange V, Balança B, Haïne M, Guichon C, Leroy C, Simon M, Malapert A, Roche M, Pialat JB, Jallades L, Lepape A, Friggeri A, Falandry C. Prognosis of Old Intensive Care COVID-19 Patients at a Glance: The Senior COVID Study. Turk J Anaesthesiol Reanim 2022; 50:S57-S61. [PMID: 35775799 PMCID: PMC9629196 DOI: 10.5152/tjar.2022.21321] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Accepted: 11/01/2021] [Indexed: 11/28/2023] Open
Abstract
OBJECTIVE Admission in the intensive care unit of the old patient with coronavirus disease 19 raises an ethical question concerning the scarce resources and their short-term mortality. METHODS Patients aged over 60 from 7 different intensive care units admitted between March 1, 2020 and May 6, 2020, with a diagnosis of coronavirus disease 19 were included in the cohort. Twenty variables were collected during the admission, such as age, severity (Simplified Acute Physiology Score [SAPS] II), several data on physiological status before intensive care unit comorbidities, evaluation of autonomy, frailty, and biological variables. The objective was to model the 30-day mortality with relevant variables, compute their odds ratio associated with their 95% CI, and produce a nomogram to easily estimate and communicate the 30-day mortality. The performance of the model was estimated with the area under the receiving operating curve. RESULTS We included 231 patients, among them 60 (26.0%) patients have died on the 30th day. The relevant variables selected to explain the 30-day mortality were Instrumental Activities of Daily Living (IADL) score (0.82 [0.71-0.94]), age 1.12 (1.07-1.18), SAPS II 1.05 (1.02-1.08), and dementia 6.22 (1.00-38.58). A nomogram was computed to visually represent the final model. Area under the receiving operating curve was at 0.833 (0.776-0.889). CONCLUSIONS Age, autonomy, dementia, and severity at admission were important predictive variables for the 30-day mortality status, and the nomogram could help the physician in the decision-making process and the communication with the family.
Collapse
Affiliation(s)
- Charles-Hervé Vacheron
- Department of Anaesthesiology and Reanimation, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
- Biometrics and Evolutionary Biology Laboratory, Biostatistics-Health Team, Hospices Civils de Lyon, Villeurbanne, France
- Division of Public Health, Department of Biostatistics and Bioinformatics, Lyon, France
| | - Laurent Bitker
- Department of Intensive Medicine and Resuscitation, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - Fabrice Thiolliére
- Department of Anaesthesiology and Reanimation, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Fabien Subtil
- Biometrics and Evolutionary Biology Laboratory, Biostatistics-Health Team, Hospices Civils de Lyon, Villeurbanne, France
| | - Paul Abraham
- Department of Anaesthesia and Resuscitation, Édouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
- Claude Bernard University Faculty of Medicine, Lyon, France
| | | | - Baptiste Balança
- Department of Anaesthesia and Resuscitation, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Lyon, France
| | - Max Haïne
- North West Hospital of Villefranche, France
| | - Céline Guichon
- Inter-University Laboratory of Human Movement Biology, Villeurbanne, France
- Department of Anaesthesia and Surgical Resuscitation, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - Christophe Leroy
- Department of Intensive Care Medicine, Emile Roux Hospital Center, le Puy en Velay, France
| | - Marie Simon
- Department of Anaesthesia and Resuscitation, Édouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | - Amélie Malapert
- Plateforme IC-HCL, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Mélanie Roche
- Plateforme IC-HCL, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | | | - Laurent Jallades
- Department of Biological Hematology, Lyon Sud Hospital South Biology and Pathology Center, Pierre-Bénite, France
| | - Alain Lepape
- Department of Intensive Care, Henry Gabrielle Hospital, Hospices Civils de Lyon, Lyon, France
- Department of Critical Care, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France
| | - Arnaud Friggeri
- Department of Anaesthesiology and Reanimation, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Claire Falandry
- Division of Geriatrics, Center Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
7
|
Hoummady S, Fantinati M, Maso D, Bynens A, Banuls D, Santos NR, Roche M, Priymenko N. Comparison of canine owner profile according to food choice: an online preliminary survey in France. BMC Vet Res 2022; 18:163. [PMID: 35509073 PMCID: PMC9066993 DOI: 10.1186/s12917-022-03258-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Accepted: 04/20/2022] [Indexed: 12/02/2022] Open
Abstract
Background Nowadays, more people are treating dogs as family members. This reflects their increased attention towards their nutrition, with renewed interest for non-conventional diets such as Biologically Appropriate Raw Food/ Bones and Raw Food in United States (BARF) or homemade. In previous studies, owners feeding their dog non-conventional diets reported lower levels of trust in veterinary advice. The aim of the study was to identify differences in lifestyle between owners feeding dogs non-conventional diets and those feeding conventional diets (i.e., dry/wet pet food) to give further insight for improving communication between veterinarians and owners. Results A total of 426 surveys were usable. Fifteen percent of the participants lived in the metropole of Paris and had more than one dog (mean 1.72 dogs). Thirty-eight percent of the survey respondents stated that their dogs were fed exclusively with non-conventional diets, while 55% declared using conventional diets alone (not considering treats). The study canine population was for the most part neutered (63%) and purebred (68%). Amongst owners feeding conventional diets exclusively, 47% determined how much food to feed by consulting the feeding guidelines on the packaging, and only 28% said that the amount of food was prescribed by their veterinarian or veterinary nurse. Out of the participants feeding non-conventional diets, 65% declared that the information for formulating the recipes was gathered on the internet or in non-veterinary books. When compared with owners feeding exclusively conventional diets, those feeding non-conventional diets were living more frequently outside the metropole of Paris, had fewer children (0.23 ± 0.57 vs 0.37 ± 0.78; p = 0.03) and had more frequently other animals. They also dewormed less often their pets, walked their dog more each day (91 vs 78%; p < 0.001) and without leash for more than 6 h per week (46 vs 31%; p = 0.003). Conclusions This survey described differences in the habits of owners feeding dogs non-conventional diets in comparison with those feeding conventional diets. Data suggest that owners using non-conventional diets may be more attentive to the ethological needs of their dog which could be a starting point for practitioners for achieving better client-veterinarian communication. Supplementary Information The online version contains supplementary material available at 10.1186/s12917-022-03258-9.
Collapse
Affiliation(s)
- S Hoummady
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, UMES, 7 avenue du Général de Gaulle, 94704, Maisons-Alfort, France.
| | - M Fantinati
- École Nationale Vétérinaire de Toulouse, 23 chemin des Capelles, 31300, Toulouse, France
| | - D Maso
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, CHUVA, 7 avenue du Général de Gaulle, 94704, Maisons-Alfort, France
| | - A Bynens
- FACCO, 46 Boulevard de Magenta, 75010, Paris, France
| | - D Banuls
- École Nationale Vétérinaire de Toulouse, 23 chemin des Capelles, 31300, Toulouse, France
| | - N R Santos
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, CHUVA, 7 avenue du Général de Gaulle, 94704, Maisons-Alfort, France
| | - M Roche
- École Nationale Vétérinaire de Toulouse, 23 chemin des Capelles, 31300, Toulouse, France
| | - N Priymenko
- TOXALIM, Université de Toulouse, Institut National de La Recherche Agronomique (INRA), École Nationale Vétérinaire de Toulouse (ENVT), BP 87614, 23 chemin des Capelles, 31076, Toulouse cedex, France
| |
Collapse
|
8
|
Desurmont GA, Tannières M, Roche M, Blanchet A, Manoukis NC. Identifying an Optimal Screen Mesh to Enable Augmentorium-Based Enhanced Biological Control of the Olive Fruit Fly Bactrocera oleae (Diptera: Tephritidae) and the Mediterranean Fruit Fly Ceratitis capitata (Diptera: Tephritidae). J Insect Sci 2022; 22:11. [PMID: 35640027 PMCID: PMC9154345 DOI: 10.1093/jisesa/ieac027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Indexed: 06/15/2023]
Abstract
The augmentorium is a cost-effective screened enclosure designed to receive fruits infested with insect pests, retain the pests inside but let their natural enemies escape to enhance biological control of pest populations. Screen selection is critical to ensure that an augmentorium is effective for a particular system. Here we tested five types of screens with a mini-augmentorium design and measured the escape of four insect species under laboratory conditions: the pests olive fruit fly Bactocera oleae (Rossi) (Diptera: Tephritidae) and Mediterranean fruit fly Ceratitis capitata (Wiedemann) (Diptera: Tephritidae), and the parasitoids Psyttalia lounsburyi (Silvestri) (Hymenoptera: Braconidae) and Psyttalia ponerophaga (Silvestri) (Hymenoptera: Braconidae). The sex ratio of insects that escaped the screens was compared to the sex ratio of insects that could not escape. Results showed that one screen type ('crystal mesh') was the best for the purpose of designing a functional augmentorium: it retained 90% of B. oleae adults and 100% of C. capitata adults while letting 72% of Psyttalia lounsburyi adults and 94% of P. ponerophaga adults escape. The other screen types tested were suboptimal, either because they let too many flies freely escape or because they retained too many parasitoids. Sex ratio was almost always similar for insects that managed to escape the screens and insects that were retained, except for P. ponerophaga and the screen type 'light mesh'. These results are promising for the development of a functional augmentorium against the olive fruit fly and further implementation against Mediterranean fruit fly.
Collapse
Affiliation(s)
| | - M Tannières
- USDA-ARS-European Biological Control Laboratory, Campus International de Baillarguet, Montferrier sur lez, France
| | - M Roche
- USDA-ARS-European Biological Control Laboratory, Campus International de Baillarguet, Montferrier sur lez, France
| | - A Blanchet
- USDA-ARS-European Biological Control Laboratory, Campus International de Baillarguet, Montferrier sur lez, France
| | - N C Manoukis
- USDA-ARS-Daniel K. Inouye U.S. Pacific Basin Agricultural Research Center, Hilo, HI 96720, USA
| |
Collapse
|
9
|
Schaeffer C, Interdonato R, Lancelot R, Roche M, Teisseire M. Social Network Data and Epidemiological Intelligence: A Case Study of Avian Influenza. Int J Infect Dis 2022. [DOI: 10.1016/j.ijid.2021.12.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
10
|
Drareni K, Mercier C, Dougkas A, Roux P, Fingal C, Labrosse H, Farsi F, Dayde D, Roche M, Nazare JA, Bruyas A, Maucort-Boulch D, Fournel A, Bensafi M, Mourier V, Giboreau A. Développement et validation d’un questionnaire d’évaluation de la Qualité de Vie Alimentaire (QVA) chez les patients atteints de cancer. NUTR CLIN METAB 2022. [DOI: 10.1016/j.nupar.2021.12.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Barbosa E, Wolinska A, Feighery C, Roche M, Szontagh-Kishazi P. Subcutaneous vacuoles with suppuration and granulomas: a histological clue to atypical mycobacterial infection. Clin Exp Dermatol 2021; 47:765-767. [PMID: 34856003 DOI: 10.1111/ced.15043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Revised: 11/20/2021] [Accepted: 11/24/2021] [Indexed: 11/29/2022]
Abstract
An 83-year-old woman was referred to the Dermatology department with a papular eruption on her left arm, occurring below the scar site of a malignant melanoma in situ, which had been excised 6 months previously. On physical examination, multiple, tender, violaceous papules and nodules inferior to the scar were noted, with central pustules in some of the lesions.
Collapse
Affiliation(s)
- E Barbosa
- Departments of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Ireland
| | - A Wolinska
- Departments of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Ireland
| | - C Feighery
- Departments of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Ireland
| | - M Roche
- Departments of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Ireland
| | - P Szontagh-Kishazi
- Departments of Pathology, Our Lady of Lourdes Hospital, Drogheda, Ireland
| |
Collapse
|
12
|
Beatty P, Killion L, Power R, Roche M. Dystrophic calcinosis cutis successfully treated with extracorporeal shockwave lithotripsy. Clin Exp Dermatol 2021; 46:1656-1658. [PMID: 34505309 DOI: 10.1111/ced.14857] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/20/2021] [Indexed: 12/01/2022]
Abstract
This case illustrates a presentation with dystrophic calcinosis cutis recalcitrant to several treatment modalities. Treatment with extracorporeal shockwave lithotripsy was initiated with near complete resolution of calcium deposits.
Collapse
Affiliation(s)
- P Beatty
- Department of Dermatology, Beaumont Hospital, Dublin, Ireland
| | - L Killion
- Department of Dermatology, Beaumont Hospital, Dublin, Ireland
| | - R Power
- Department of Urology, Beaumont Hospital, Dublin, Ireland
| | - M Roche
- Department of Dermatology, Beaumont Hospital, Dublin, Ireland
| |
Collapse
|
13
|
Roche M, Mircher C, Toulas J, Prioux E, Conte M, Ravel A, Falquero S, Labidi A, Stora S, Durand S, Mégarbané A, Cieuta-Walti C. Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome. J Intellect Disabil Res 2021; 65:795-800. [PMID: 33880800 DOI: 10.1111/jir.12832] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Revised: 02/14/2021] [Accepted: 02/21/2021] [Indexed: 06/12/2023]
Abstract
BACKGROUND Attention deficit hyperactivity disorder (ADHD) is a common co-morbidity that affects up to 44% of children with Down syndrome (DS). There is a need for reliable, good quality research on the use of methylphenidate within this population. The objective of this study is to report our experience regarding the management of ADHD in these children using methylphenidate. METHODS This study is a retrospective observation of 21 children with DS, followed at Jérôme Lejeune Institute between 2000 and 2018. The diagnosis of ADHD was made using the Diagnostic and Statistical Manual of Mental Disorders criteria. Efficacy was measured as response or non-response on two main symptoms: attention/concentration and hyperactivity/impulsivity. Safety was evaluated by the presence or absence of side effects. RESULTS Sixteen out of the 21 children (76%) showed improvement with methylphenidate. The average age of treatment onset in responding children was 8 years and 10 months versus 6 years and 3 months in non-responders (P = 0.05). Average dose/weight was significantly different in responders and non-responders (0.82 vs. 0.54 mg/kg/day, respectively; P = 0.03). Twelve children out of 21 (57%) experienced side effects; only three experienced side effects severe enough to require treatment interruption. Most common side effects were loss of appetite and difficulties in falling asleep. CONCLUSION Methylphenidate was effective and safe in treating ADHD in 76% of cases in children with DS, with few serious side effects to report. Early diagnosis of ADHD is important to improve the quality of life, learning, inclusion and socialisation of children with DS.
Collapse
Affiliation(s)
- M Roche
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - C Mircher
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - J Toulas
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - E Prioux
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - M Conte
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - A Ravel
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - S Falquero
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - A Labidi
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - S Stora
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - S Durand
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
| | - A Mégarbané
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
- Department of Human Genetics, Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos, Lebanon
| | - C Cieuta-Walti
- CRB BioJeL, Institut Jérôme Lejeune, Paris, France
- Department of Pediatric Neurology, Sherbrooke Medical University, Sherbrooke, Quebec, Canada
| |
Collapse
|
14
|
Falandry C, Malapert A, Roche M, Subtil F, Berthiller J, Boin C, Dubreuil J, Ravot C, Bitker L, Abraham P, Collange V, Balança B, Goutte S, Guichon C, Gadea E, Argaud L, Dayde D, Jallades L, Lepape A, Pialat JB, Friggeri A, Thiollière F. Risk factors associated with day-30 mortality in patients over 60 years old admitted in ICU for severe COVID-19: the Senior-COVID-Rea Multicentre Survey protocol. BMJ Open 2021; 11:e044449. [PMID: 34230013 PMCID: PMC8264162 DOI: 10.1136/bmjopen-2020-044449] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
INTRODUCTION With the spread of COVID-19 epidemic, health plans must be adapted continuously. There is an urgent need to define the best care courses of patients with COVID-19, especially in intensive care units (ICUs), according to their individualised benefit/risk ratio. Since older age is associated with poorer short-term and long-term outcomes, prediction models are needed, that may assist clinicians in their ICU admission decision. Senior-COVID-Rea was designed to evaluate, in patients over 60 years old admitted in ICU for severe COVID-19 disease, the impact of age and geriatric and paraclinical parameters on their mortality 30 days after ICU admission. METHODS AND ANALYSIS This is a multicentre survey protocol to be conducted in seven hospitals of the Auvergne-Rhône-Alpes region, France. All patients over 60 years old admitted in ICU for severe COVID-19 infection (or their legally acceptable representative) will be proposed to enter the study and to fill in a questionnaire regarding their functional and nutritional parameters 1 month before COVID-19 infection. Paraclinical parameters at ICU admission will be collected: lymphocytes and neutrophils counts, high-fluorescent lymphoid cells and immature granulocytes percentages (Sysmex data), D-dimers, C-reactive protein, lactate dehydrogenase (LDH), creatinine, CT scan for lung extension rate as well as clinical resuscitation scores, and the delay between the first signs of infection and ICU admission. The primary outcome will be the overall survival at day 30 post-ICU admission. The analysis of factors predicting mortality at day 30 will be carried out using univariate and multivariate logistic regressions. Multivariate logistic regression will consider up to 15 factors.The ambition of this trial, which takes into account the different approaches of geriatric vulnerability, is to define the respective abilities of different operational criteria of frailty to predict patients' outcomes. ETHICS AND DISSEMINATION The study protocol was ethically approved. The results of the primary and secondary objectives will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT04422340.
Collapse
Affiliation(s)
- Claire Falandry
- Service de Gériatrie, Centre Hospitaliser Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
- Laboratoire CarMeN, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Faculté de Médecine et de Maïeutique Charles Mérieux, Université de Lyon, Oullins, France
| | - Amélie Malapert
- Plateforme Transversale de Recherche de l'ICHCL, C, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Mélanie Roche
- Plateforme Transversale de Recherche de l'ICHCL, C, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Fabien Subtil
- CNRS UMR5558, Laboratoire de Biométrie et Biologie Evolutive, Université Claude Bernard Lyon 1, Université de Lyon, Villeurbanne, France
- Service de Biostatistique, Hospices Civils de Lyon, Lyon, France
| | - Julien Berthiller
- Université Claude Bernard Lyon 1 - Domaine de Rockefeller, Lyon, France
- SREC - PSP - Cellule innovation, Hospices Civils de Lyon, Bron, France
| | | | - Justine Dubreuil
- Plateforme Transversale de Recherche de l'ICHCL - Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Christine Ravot
- Service de Gériatrie, Centre Hospitaliser Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Laurent Bitker
- Service de Réanimation Médicale, Hôpital de La Croix Rousse, Hospices Civils de Lyon, Lyon, France
- CREATIS INSERM 1044 CNRS 5220, Université de Lyon, Lyon, France
| | - Paul Abraham
- Département d'anesthésie-réanimation, Hôpital Edouard-Herriot, Hospices Civils de Lyon, Lyon, France
| | - Vincent Collange
- Département Anesthésie-réanimation, Medipôle Lyon-Villeurbanne, Villeurbanne, France
| | - Baptiste Balança
- Département d'anesthésie et réanimation neurologique, Hôpital Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France
- Inserm U1028, CNRS UMR 5292, Lyon Neuroscience Research Centre, Team TIGER, University of Lyon, Lyon, France
| | - Sylvie Goutte
- Service de gériatrie, Hôpital Nord-Ouest, Gleizé, France
| | - Céline Guichon
- Service d'anesthésie - réanimation, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
- Université Lyon 1, Université de Lyon, Lyon, France
| | - Emilie Gadea
- Département de Recherche Clinique, Centre Hospitalier Emile Roux, Le Puy en Velay, France
| | - Laurent Argaud
- Faculté de médecine Lyon-Est, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
- Service de Médecine Intensive-Réanimation Médicale, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - David Dayde
- Plateforme Transversale de Recherche de l'ICHCL, C, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Laurent Jallades
- Service d'Hématologie biologique - Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Alain Lepape
- Intensive Care Unit, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, Lyon, France
| | - Jean-Baptiste Pialat
- Département de Radiologie, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France
- CREATIS CNRS UMR 5220 INSERM U1206, Université de Lyon, Lyon, France
| | - Arnaud Friggeri
- Intensive Care Unit, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Fabrice Thiollière
- Intensive Care Unit, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
15
|
Roche M, Ravot C, Malapert A, Paget-Bailly S, Garandeau C, Pitiot V, Tomatis M, Riche B, Galamand B, Granger M, Barbavara C, Bourgeois C, Genest E, Stefani L, Haïne M, Castel-Kremer E, Morel-Soldner I, Collange V, Le Saux O, Dayde D, Falandry C. Feasibility of a prehabilitation programme dedicated to older patients with cancer before complex medical-surgical procedures: the PROADAPT pilot study protocol. BMJ Open 2021; 11:e042960. [PMID: 33811052 PMCID: PMC8023742 DOI: 10.1136/bmjopen-2020-042960] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 02/20/2021] [Accepted: 02/26/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Ageing is associated with an increased prevalence of comorbidities and sarcopenia as well as a decline of functional reserve of multiple organ systems, which may lead, in the context of the disease-related and/or treatment-related stress, to functional deconditioning. The multicomponent 'Prehabilitation & Rehabilitation in Oncogeriatrics: Adaptation to Deconditioning risk and Accompaniment of Patients' Trajectories (PROADAPT)' intervention was developed multiprofessionally to implement prehabilitation in older patients with cancer. METHODS The PROADAPT pilot study is an interventional, non-comparative, prospective, multicentre study. It will include 122 patients oriented to complex medical-surgical curative procedures (major surgery or radiation therapy with or without chemotherapy). After informed consent, patients will undergo a comprehensive geriatric assessment and will be offered a prehabilitation kit that includes an advice booklet with personalised objectives and respiratory rehabilitation devices. Patients will then be called weekly and monitored for physical and respiratory rehabilitation, preoperative renutrition, motivational counselling and iatrogenic prevention. Six outpatient visits will be planned: at inclusion, a few days before the procedure and at 1, 3, 6 and 12 months after the end of the procedure. The main outcome of the study is the feasibility of the intervention, defined as the ability to perform at least one of the components of the programme. Clinical data collected will include patient-specific and cancer-specific characteristics. ETHICS AND DISSEMINATION The study protocol was approved by the Ile de France 8 ethics committee on 5 June 2018. The results of the primary and secondary objectives will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT03659123. Pre-results of the trial.
Collapse
Affiliation(s)
- Mélanie Roche
- Plateforme Transversale de Recherche de l'IC-HCL, Hospices Civils de Lyon, Lyon, France
| | - Christine Ravot
- Geriatrics Unit, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Amélie Malapert
- Plateforme Transversale de Recherche de l'IC-HCL, Hospices Civils de Lyon, Lyon, France
| | - Sophie Paget-Bailly
- Methodology and Quality of Life Unit in Oncology, University Hospital Centre Besancon, Besancon, France
- INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Université Bourgogne Franche-Comté, Besancon, France
| | - Charlène Garandeau
- Direction à la Recherche Clinique et à l'Innovation, Hospices Civils de Lyon, Lyon, France
| | - Virginie Pitiot
- Plateforme Transversale de Recherche de l'IC-HCL, Hospices Civils de Lyon, Lyon, France
| | - Mélanie Tomatis
- Geriatrics Unit, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Benjamin Riche
- Service de Biostatistique - Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France
- Laboratoire de Biométrie et Biologie Évolutive CNRS UMR 5558, Équipe Biostatistiques Santé, Université de Lyon, Lyon, France
| | - Béatrice Galamand
- Geriatrics Unit, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Marion Granger
- Geriatrics Unit, Hospices Civils de Lyon, Lyon, France
- Centre Hospitalier de Chambery, Chambery, France
| | | | - Chrystelle Bourgeois
- Department of Medical Oncology, Centre Hospitalier Annecy Genevois, Pringy, France
| | | | - Laetitia Stefani
- Department of Medical Oncology, Centre Hospitalier Annecy Genevois, Pringy, France
| | - Max Haïne
- Pôle de gérontologie et Médecine de Réadaptation, Hôpital Nord-Ouest, Villefranche-sur-Saone, France
| | | | - Isabelle Morel-Soldner
- Geriatrics Unit, Centre Hospitalier de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - Vincent Collange
- Département anesthésie réanimation, Medipole Lyon-Villeurbanne, Villeurbanne, France
| | - Olivia Le Saux
- Therapeutic targeting of the tumor cell and its immune microenvironment, Centre de Recherche en Cancerologie de Lyon, Lyon, France
| | - David Dayde
- Plateforme Transversale de Recherche de l'IC-HCL, Hospices Civils de Lyon, Lyon, France
| | - Claire Falandry
- Geriatrics Unit, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
- CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Charles Mérieux Medical School, Oullins, France
| |
Collapse
|
16
|
Geia L, Baird K, Bail K, Barclay L, Bennett J, Best O, Birks M, Blackley L, Blackman R, Bonner A, Bryant AO R, Buzzacott C, Campbell S, Catling C, Chamberlain C, Cox L, Cross W, Cruickshank M, Cummins A, Dahlen H, Daly J, Darbyshire P, Davidson P, Denney-Wilson E, De Souza R, Doyle K, Drummond A, Duff J, Duffield C, Dunning T, East L, Elliott D, Elmir R, Fergie OAM D, Ferguson C, Fernandez R, Flower AM D, Foureur M, Fowler C, Fry M, Gorman E, Grant J, Gray J, Halcomb E, Hart B, Hartz D, Hazelton M, Heaton L, Hickman L, Homer AO CSE, Hungerford C, Hutton A, Jackson AO D, Johnson A, Kelly MA, Kitson A, Knight S, Levett-Jones T, Lindsay D, Lovett R, Luck L, Molloy L, Manias E, Mannix J, Marriott AMR, Martin M, Massey D, McCloughen A, McGough S, McGrath L, Mills J, Mitchell BG, Mohamed J, Montayre J, Moroney T, Moyle W, Moxham L, Northam OAM H, Nowlan S, O'Brien AP, Ogunsiji O, Paterson C, Pennington K, Peters K, Phillips J, Power T, Procter N, Ramjan L, Ramsay N, Rasmussen B, Rihari-Thomas J, Rind B, Robinson M, Roche M, Sainsbury K, Salamonson Y, Sherwood J, Shields L, Sim J, Skinner I, Smallwood G, Smallwood R, Stewart L, Taylor S, Usher AM K, Virdun C, Wannell J, Ward R, West C, West R, Wilkes L, Williams R, Wilson R, Wynaden D, Wynne R. A unified call to action from Australian nursing and midwifery leaders: ensuring that Black lives matter. Contemp Nurse 2020; 56:297-308. [DOI: 10.1080/10376178.2020.1809107] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- L. Geia
- James Cook University, Townsville, QLD, Australia
| | - K. Baird
- University of Technology Sydney, Sydney, NSW, Australia
| | - K. Bail
- University of Canberra, Canberra, ACT, Australia
| | - L. Barclay
- University of Sydney, Sydney, NSW, Australia
| | - J. Bennett
- University of Newcastle, Callaghan, NSW, Australia
| | - O. Best
- University of Southern Queensland, Darling Heights, QLD, Australia
| | - M. Birks
- James Cook University, Townsville, QLD, Australia
| | - L. Blackley
- Queensland Health, Joyce Palmer Health Service, Palm Island, QLD, Australia
| | - R. Blackman
- Gidgee Healing Mt Isa, Mount Isa, QLD, Australia
| | - A. Bonner
- Griffith University, Brisbane, QLD, Australia
| | - R. Bryant AO
- Rosemary Bryant Foundation, South Australia, Australia
| | - C. Buzzacott
- Rhodanthe Lipsett Indigenous Midwifery Charitable Fund, Caringbah, NSW, Australia
| | - S. Campbell
- Charles Darwin University, Darwin, NT, Australia
| | - C. Catling
- University of Technology Sydney, Sydney, NSW, Australia
| | | | - L. Cox
- Queensland University of Technology, Brisbane, QLD, Australia
| | - W. Cross
- Federation University, Ballarat, VIC, Australia
| | - M. Cruickshank
- University of Technology Sydney, Sydney, NSW, Australia
- Sydney Children’s Hospital Network, Sydney, NSW, Australia
| | - A. Cummins
- University of Technology Sydney, Sydney, NSW, Australia
| | - H. Dahlen
- Western Sydney University, Sydney, NSW, Australia
| | - J. Daly
- University of Sydney, Sydney, NSW, Australia
| | - P. Darbyshire
- Philip Darbyshire Consulting, Highbury, South Australia, Australia
| | - P. Davidson
- University of Technology Sydney, Sydney, NSW, Australia
- Western Sydney University, Sydney, NSW, Australia
- John Hopkins University, Baltimore, USA
| | | | | | - K. Doyle
- Western Sydney University, Sydney, NSW, Australia
| | - A. Drummond
- Queensland University of Technology, Brisbane, QLD, Australia
| | - J. Duff
- Queensland University of Technology, Brisbane, QLD, Australia
| | - C. Duffield
- University of Technology Sydney, Sydney, NSW, Australia
- Edith Cowan University, Perth, Western Australia, Australia
| | - T. Dunning
- Deakin University, Melbourne, VIC, Australia
| | - L. East
- University of New England, Armidale, NSW, Australia
| | - D. Elliott
- University of Technology Sydney, Sydney, NSW, Australia
| | - R. Elmir
- Western Sydney University, Sydney, NSW, Australia
| | - D. Fergie OAM
- Australian Catholic University, Fitzroy, VIC, Australia
| | - C. Ferguson
- Western Sydney University, Sydney, NSW, Australia
| | - R. Fernandez
- University of Wollongong, Keiraville, NSW, Australia
| | | | - M. Foureur
- University of Newcastle, Callaghan, NSW, Australia
| | - C. Fowler
- University of Technology Sydney, Sydney, NSW, Australia
| | - M. Fry
- University of Technology Sydney, Sydney, NSW, Australia
| | - E. Gorman
- New South Wales Health, Sydney, NSW, Australia
| | - J. Grant
- Charles Sturt University, Dubbo, NSW, Australia
| | - J. Gray
- University of Technology Sydney, Sydney, NSW, Australia
| | - E. Halcomb
- University of Wollongong, Keiraville, NSW, Australia
| | - B. Hart
- University of Notre Dame, Darlinghurst, NSW, Australia
| | - D. Hartz
- Charles Darwin University, Darwin, NT, Australia
| | - M. Hazelton
- University of Newcastle, Callaghan, NSW, Australia
| | - L. Heaton
- Western Sydney University, Sydney, NSW, Australia
| | - L. Hickman
- University of Technology Sydney, Sydney, NSW, Australia
- Contemporary Nurse Journal
| | | | | | - A. Hutton
- University of Newcastle, Callaghan, NSW, Australia
| | - D. Jackson AO
- University of Technology Sydney, Sydney, NSW, Australia
| | - A. Johnson
- University of Newcastle, Callaghan, NSW, Australia
| | - M. A. Kelly
- Sydney Children’s Hospital Network, Sydney, NSW, Australia
| | - A. Kitson
- Western Sydney University, Sydney, NSW, Australia
| | - S. Knight
- James Cook University, Townsville, QLD, Australia
| | | | - D. Lindsay
- James Cook University, Townsville, QLD, Australia
| | - R. Lovett
- Australian National University, Canberra, Australian Capital Territory, Australia
| | - L. Luck
- Western Sydney University, Sydney, NSW, Australia
| | - L. Molloy
- University of Wollongong, Keiraville, NSW, Australia
| | - E. Manias
- Deakin University, Melbourne, VIC, Australia
| | - J. Mannix
- Western Sydney University, Sydney, NSW, Australia
| | | | - M. Martin
- Queensland Aboriginal and Islander Health Council, Brisbane, QLD, Australia
| | - D. Massey
- Southern Cross University, Gold Coast Campus, QLD, Australia
| | | | - S. McGough
- Curtin University, Perth, Western Australia, Australia
| | - L. McGrath
- Aboriginal Medical Service Redfern, Sydney, NSW, Australia
| | - J. Mills
- La Trobe University, Melbourne, VIC, Australia
| | | | - J. Mohamed
- Lowitja Institute, Melbourne, VIC, Australia
| | - J. Montayre
- Western Sydney University, Sydney, NSW, Australia
| | - T. Moroney
- University of Wollongong, Keiraville, NSW, Australia
| | - W. Moyle
- Griffith University, Brisbane, QLD, Australia
| | - L. Moxham
- University of Wollongong, Keiraville, NSW, Australia
| | | | - S. Nowlan
- Queensland Health, Joyce Palmer Health Service, Palm Island, QLD, Australia
| | | | - O. Ogunsiji
- Western Sydney University, Sydney, NSW, Australia
| | - C. Paterson
- University of Canberra, Canberra, ACT, Australia
| | - K. Pennington
- Flinders University, Adelaide, South Australia, Australia
| | - K. Peters
- Western Sydney University, Sydney, NSW, Australia
| | - J. Phillips
- University of Technology Sydney, Sydney, NSW, Australia
| | - T. Power
- University of Technology Sydney, Sydney, NSW, Australia
| | - N. Procter
- University of South Australia, Adelaide, South Australia, Australia
| | - L. Ramjan
- Western Sydney University, Sydney, NSW, Australia
| | - N. Ramsay
- Queensland Health, Joyce Palmer Health Service, Palm Island, QLD, Australia
| | | | | | - B. Rind
- Aboriginal Health Unit Mt Druitt Hospital, Sydney, NSW, Australia
| | - M. Robinson
- Murdoch University, Perth, Western Australia, Australia
| | - M. Roche
- University of Technology Sydney, Sydney, NSW, Australia
| | - K. Sainsbury
- University of Canberra, Canberra, ACT, Australia
| | | | - J. Sherwood
- Charles Sturt University, Dubbo, NSW, Australia
| | - L. Shields
- University of Queensland, Brisbane, QLD, Australia
| | - J. Sim
- University of Wollongong, Keiraville, NSW, Australia
| | - I. Skinner
- James Cook University, Townsville, QLD, Australia
| | - G. Smallwood
- James Cook University, Townsville, QLD, Australia
| | - R. Smallwood
- University of Newcastle, Callaghan, NSW, Australia
- University of New England, Armidale, NSW, Australia
| | - L. Stewart
- James Cook University, Townsville, QLD, Australia
| | - S. Taylor
- Top End Health, Northern Territory, Darwin, NT, Australia
| | - K. Usher AM
- University of Technology Sydney, Sydney, NSW, Australia
- University of New England, Armidale, NSW, Australia
| | - C. Virdun
- University of Technology Sydney, Sydney, NSW, Australia
| | - J. Wannell
- Melbourne Poche Centre for Indigenous Health, Melbourne, VIC, Australia
| | - R. Ward
- University of Southern Queensland, Darling Heights, QLD, Australia
| | - C. West
- James Cook University, Townsville, QLD, Australia
| | - R. West
- Griffith University, Brisbane, QLD, Australia
| | - L. Wilkes
- Western Sydney University, Sydney, NSW, Australia
| | - R. Williams
- Charles Darwin University, Darwin, NT, Australia
| | - R. Wilson
- University of Newcastle, Callaghan, NSW, Australia
- University of New England, Armidale, NSW, Australia
| | - D. Wynaden
- Curtin University, Perth, Western Australia, Australia
| | - R. Wynne
- Western Sydney University, Sydney, NSW, Australia
| |
Collapse
|
17
|
Abstract
Development of genetic testing direct-to-consumer (DTC) for recreational purposes, although prohibited in France, is a real challenge to the current practice of gamete donation. Indeed, anonymity is a fundamental principle contributing to the ethics of donation. This principle is weakened due to the availability to the general public of these tests on the Internet. Several thousands of people are conceived by gamete donation worldwide, some of whom do not know how they were conceived. Gamete donors should be informed that their anonymity is no longer guaranteed, as they can be found by homologies of their DNA, or that of a parent or a child, potentially available in databases. Thus, adults conceived by gamete donation but not informed by their parents can discover their way of conception. Recipients of gamete donation should also be informed that their child's DNA will establish the biological discrepancy and they should be encouraged to disclose the conception to their child. Several countries now allow children conceived by donation to obtain donor's identity. In France, the Bioethics Law is currently being finalized and will now allow access to donor's identity for people conceived by gamete donation.
Collapse
Affiliation(s)
- A-S Neyroud
- CHU Rennes, service de biologie de la reproduction-CECOS, 35000 Rennes, France; Univ Rennes, Inserm, EHESP, Irset (institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| | - M Roche
- CHU Rennes, service de biologie de la reproduction-CECOS, 35000 Rennes, France
| | - M Domin
- CHU Rennes, service de gynécologie, 35000 Rennes, France
| | - S Jaillard
- Univ Rennes, Inserm, EHESP, Irset (institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France; CHU Rennes, laboratoire de cytogénétique, 35000 Rennes, France
| | - C Ravel
- CHU Rennes, service de biologie de la reproduction-CECOS, 35000 Rennes, France; Univ Rennes, Inserm, EHESP, Irset (institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France.
| |
Collapse
|
18
|
Richard M, Specklin S, Roche M, Hinnen F, Kuhnast B. Original synthesis of radiolabeling precursors for batch and on resin one-step/late-stage radiofluorination of peptides. Chem Commun (Camb) 2020; 56:2507-2510. [PMID: 32003763 DOI: 10.1039/c9cc09434b] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Radiolabeling of peptides with fluorine-18 is hurdled by their chemical sensitivity and complicated processes. Original triflyl-pyridine intermediates afforded ammonium precursors that were radiolabeled at low temperature. From that study, a generic tag has been designed to allow a simple one-step/late-stage radiolabelling of peptides. The strategy has been transposed to an automated "on-resin" radiolabelling.
Collapse
Affiliation(s)
- Mylène Richard
- Université Paris Saclay, CEA, INSERM, CNRS, BioMaps, Service Hospitalier Frédéric Joliot, Bertrand KUHNAST, 4 place du général Leclerc, 91401 Orsay, France.
| | | | | | | | | |
Collapse
|
19
|
Keeling E, Murray S, Williams Y, Sexton D, O'Kelly P, Deady S, O'Leary E, Dorman A, Roche M, Ni Raghallaigh S, McCormick A, Moloney F, O'Neill J, Conlon P. Merkel cell carcinoma in kidney transplant recipients in Ireland 1964–2018. Br J Dermatol 2019; 181:1314-1315. [DOI: 10.1111/bjd.18218] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- E. Keeling
- Department of Dermatology Head & Neck Surgery, Beaumont Hospital Dublin Ireland
| | - S.L. Murray
- Department of Nephrology & Transplantation Head & Neck Surgery, Beaumont Hospital Dublin Ireland
| | - Y. Williams
- Department of Nephrology & Transplantation Head & Neck Surgery, Beaumont Hospital Dublin Ireland
| | - D.J. Sexton
- Department of Nephrology & Transplantation Head & Neck Surgery, Beaumont Hospital Dublin Ireland
| | - P. O'Kelly
- Department of Nephrology & Transplantation Head & Neck Surgery, Beaumont Hospital Dublin Ireland
| | - S. Deady
- National Cancer Registry Ireland
| | | | - A. Dorman
- Department of Pathology Head & Neck Surgery, Beaumont Hospital Dublin Ireland
| | - M. Roche
- Department of Dermatology Head & Neck Surgery, Beaumont Hospital Dublin Ireland
| | - S. Ni Raghallaigh
- Department of Dermatology Head & Neck Surgery, Beaumont Hospital Dublin Ireland
| | - A. McCormick
- Department of Hepatology & Liver Transplant St Vincent's Hospital Dublin Ireland
| | - F.J. Moloney
- Department of Dermatology Mater University Hospital Dublin Ireland
| | - J.P. O'Neill
- Department of Otolaryngology Head & Neck Surgery, Beaumont Hospital Dublin Ireland
| | - P.J. Conlon
- Department of Nephrology & Transplantation Head & Neck Surgery, Beaumont Hospital Dublin Ireland
- Department of Medicine Royal College of Surgeons in Ireland Dublin Ireland
| |
Collapse
|
20
|
O'Keeffe C, Hollywood A, Hanley B, Boggs J, Roche M, Feighery C. Eruptive melanocytic naevi provoked by sunbed use in a patient on systemic immunosuppression. Clin Exp Dermatol 2019; 45:273-274. [PMID: 31389065 DOI: 10.1111/ced.14067] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/05/2019] [Indexed: 11/28/2022]
Affiliation(s)
- C O'Keeffe
- Department of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland
| | - A Hollywood
- Department of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland
| | - B Hanley
- Department of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland
| | - J Boggs
- Department of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland
| | - M Roche
- Department of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland
| | - C Feighery
- Department of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland
| |
Collapse
|
21
|
Bauer S, George S, Kang Y, Jones R, Mir O, Tap W, Doyle A, Picazio N, Zhou T, Roche M, Heinrich M. VOYAGER: an open-label, randomised, phase 3 study of avapritinib vs regorafenib in patients with locally advanced metastatic or unresectable gastrointestinal stromal tumour. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.196] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
22
|
Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol 2019; 153:223-229. [PMID: 30765148 DOI: 10.1016/j.ygyno.2019.02.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 01/24/2019] [Accepted: 02/04/2019] [Indexed: 11/16/2022]
Abstract
BACKGROUND Intraperitoneal (IP) chemotherapy can improve outcomes for women with optimally cytoreduced epithelial ovarian cancer but toxicities are a concern. We conducted 2 phase 2 trials of an IV/IP regimen using carboplatin and paclitaxel without (Trial A) and with bevacizumab (Trial B). METHODS Both trials consisted of carboplatin AUC 6 day 1, and paclitaxel 60 mg/m2 on days 1,8, 15 of a 21-day cycle; in Trial B, patients received IV bevacizumab 15 mg/kg every cycle starting cycle 2. Chemotherapy was administered IV for cycle 1 and then IP for all subsequent cycles. Primary objectives included safety and tolerability, pathologic CR rate (Trial A), and the rate of completion of IP cycles of therapy (Trial B). Progression-free (PFS), overall survival (OS), and pharmacokinetic analysis were secondary endpoints. RESULTS 81 patients were treated on both trials (n = 40 and 41 in trials A and B, respectively). Median age for trials A and B was 59 (range, 36-76) and 55 (range, 19-69) years, respectively. 68% and 85% of patients, respectively for A and B, completed at least 4 cycles of treatment in both trials. Treatment with bevacizumab resulted in higher rates of grade 3 fatigue (37 versus 33%) and grade 3-4 diarrhea (22 versus 8%). Median PFS was 23.5 (95%CI 16.2-35.3) and 25 (95%CI 16.4-42.7) months, respectively; median OS was 68 (95%CI 49.5-NR) and 79.7 (95%CI 59.0-79.7) months, respectively for Trial A and B. CONCLUSIONS Weekly administered IP carboplatin and IP paclitaxel is tolerable and safe with similar activity with and without concommittant bevacizumab in these 2 trials.
Collapse
Affiliation(s)
- C N Krasner
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
| | - C Castro
- Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, United States of America
| | - R T Penson
- Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, United States of America
| | - M Roche
- Blueprint Bio, Cambridge, MA, United States of America.
| | - U A Matulonis
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America
| | - M A Morgan
- Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA, United States of America.
| | - C Drescher
- Translational Research Program, Division of Gynecologic Oncology, Fred Hutchinson Cancer Center, Seattle, WA, United States of America.
| | - D K Armstrong
- Department of Medical Oncology, Johns Hopkins University Medical Center, Baltimore, MD, United States of America.
| | - J K Wolfe
- Community Health, Indianapolis, IN, United States of America.
| | - H Lee
- Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, United States of America
| | - J G Supko
- Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, United States of America
| | - M Seiden
- US Oncology, United States of America.
| | - M J Birrer
- Department of Medical Oncology, University of Alabama, Birmingham, AL, United States of America.
| | - D S Dizon
- Department of Medical Oncology, Rhode Island Hospital, United States of America.
| |
Collapse
|
23
|
Savelli M, Roche M, Curti C, Bornet C, Rathelot P, Montana M, Vanelle P. Methods to control anticancer chemotherapy preparations ranked by risk analysis. Pharmazie 2019; 73:251-259. [PMID: 29724289 DOI: 10.1691/ph.2018.7205] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
The observed increase in cancer led to a continuous rise in anticancer drug preparations in Hospital Centres. The quality and security of these preparations are essential to ensure the efficacy and to limit the risk of iatrogenic toxicity. Several methods have been described to secure the process of preparation (i.e. non-analytical methods for the control during the fabrication; analytical methods for the final product evaluation). These different methods have been presented in many studies, in particular in descriptive studies, but in practice, selecting a method is difficult and related to needs and hospital priorities. Therefore, we decided to conduct this present review focused on various existing methods allowing enhancement in security of anti-cancer drugs preparation process. A proactive hazard analysis method was applied, considering preparation and control steps, to discuss the choice of a method in terms of quality and security and to identify potential risks of failure. The results show that none method is perfect. Methods with the lowest criticality score are the robotization closely followed by Drugcam® in the case of re-labelling of all containers. According to these elements a University Hospital Centre could consider these risk indexesimplementing control methods.
Collapse
|
24
|
Roche M, Specklin S, Richard M, Hinnen F, Génermont K, Kuhnast B. [ 18 F]FPyZIDE: A versatile prosthetic reagent for the fluorine-18 radiolabeling of biologics via copper-catalyzed or strain-promoted alkyne-azide cycloadditions. J Labelled Comp Radiopharm 2019; 62:95-108. [PMID: 30556584 DOI: 10.1002/jlcr.3701] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 12/07/2018] [Accepted: 12/11/2018] [Indexed: 11/05/2022]
Abstract
Methods for the radiolabeling of biologics with fluorine-18 have been of interest for several decades. A common approach consists in the preparation of a prosthetic reagent, a small molecule bearing a fluorine-18 that is conjugated with the macromolecule to an appropriate function. Click chemistry, and more particularly cycloadditions, is an interesting approach to radiolabel molecules thanks to mild reaction conditions, high yields, low by-products formation, and strong orthogonality. Moreover, the chemical functions involved in the cycloaddition reaction are stable in the drastic radiofluorination conditions, thus allowing a simple radiosynthetic route to prepare the prosthetic reagent. We report herein the radiosynthesis of 18 F-FPyZIDE, a pyridine-based azide-bearing prosthetic reagent. We exemplified its conjugation via copper-catalyzed cycloaddition (CuAAC) and strain-promoted cycloaddition (SPAAC) with several terminal alkyne or strained alkyne model compounds.
Collapse
Affiliation(s)
- Mélanie Roche
- IMIV, Service Hospitalier Frédéric Joliot, CEA, Inserm, Université Paris Sud, CNRS, Université Paris-Saclay, Orsay, France
| | - Simon Specklin
- IMIV, Service Hospitalier Frédéric Joliot, CEA, Inserm, Université Paris Sud, CNRS, Université Paris-Saclay, Orsay, France
| | - Mylène Richard
- IMIV, Service Hospitalier Frédéric Joliot, CEA, Inserm, Université Paris Sud, CNRS, Université Paris-Saclay, Orsay, France
| | - Françoise Hinnen
- IMIV, Service Hospitalier Frédéric Joliot, CEA, Inserm, Université Paris Sud, CNRS, Université Paris-Saclay, Orsay, France
| | - Kevin Génermont
- IMIV, Service Hospitalier Frédéric Joliot, CEA, Inserm, Université Paris Sud, CNRS, Université Paris-Saclay, Orsay, France
| | - Bertrand Kuhnast
- IMIV, Service Hospitalier Frédéric Joliot, CEA, Inserm, Université Paris Sud, CNRS, Université Paris-Saclay, Orsay, France
| |
Collapse
|
25
|
Richard M, Truillet C, Tran VL, Liu H, Porte K, Audisio D, Roche M, Jego B, Cholet S, Fenaille F, Kuhnast B, Taran F, Specklin S. New fluorine-18 pretargeting PET imaging by bioorthogonal chlorosydnone–cycloalkyne click reaction. Chem Commun (Camb) 2019; 55:10400-10403. [DOI: 10.1039/c9cc05486c] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A PET pretargeting approach using strain-promoted sydnone–alkyne cycloaddition.
Collapse
Affiliation(s)
- Mylène Richard
- UMR 1023 IMIV
- Service Hospitalier Frédéric Joliot (SHFJ)
- CEA, Inserm
- Université Paris Sud, CNRS
- Université Paris-Saclay
| | - Charles Truillet
- UMR 1023 IMIV
- Service Hospitalier Frédéric Joliot (SHFJ)
- CEA, Inserm
- Université Paris Sud, CNRS
- Université Paris-Saclay
| | - Vu Long Tran
- UMR 1023 IMIV
- Service Hospitalier Frédéric Joliot (SHFJ)
- CEA, Inserm
- Université Paris Sud, CNRS
- Université Paris-Saclay
| | - Hui Liu
- Service de Chimie Bio-organique et Marquage DRF-JOLIOT-SCBM
- CEA, Université Paris-Saclay
- 91191 Gif-sur-Yvette
- France
| | - Karine Porte
- Service de Chimie Bio-organique et Marquage DRF-JOLIOT-SCBM
- CEA, Université Paris-Saclay
- 91191 Gif-sur-Yvette
- France
| | - Davide Audisio
- Service de Chimie Bio-organique et Marquage DRF-JOLIOT-SCBM
- CEA, Université Paris-Saclay
- 91191 Gif-sur-Yvette
- France
| | - Mélanie Roche
- UMR 1023 IMIV
- Service Hospitalier Frédéric Joliot (SHFJ)
- CEA, Inserm
- Université Paris Sud, CNRS
- Université Paris-Saclay
| | - Benoit Jego
- UMR 1023 IMIV
- Service Hospitalier Frédéric Joliot (SHFJ)
- CEA, Inserm
- Université Paris Sud, CNRS
- Université Paris-Saclay
| | - Sophie Cholet
- Service de Pharmacologie et d’Immunoanalyse (SPI)
- CEA/DRF/JOLIOT
- Université Paris Saclay
- F-91191 Gif-sur-Yvette
- France
| | - François Fenaille
- Service de Pharmacologie et d’Immunoanalyse (SPI)
- CEA/DRF/JOLIOT
- Université Paris Saclay
- F-91191 Gif-sur-Yvette
- France
| | - Bertrand Kuhnast
- UMR 1023 IMIV
- Service Hospitalier Frédéric Joliot (SHFJ)
- CEA, Inserm
- Université Paris Sud, CNRS
- Université Paris-Saclay
| | - Frédéric Taran
- Service de Chimie Bio-organique et Marquage DRF-JOLIOT-SCBM
- CEA, Université Paris-Saclay
- 91191 Gif-sur-Yvette
- France
| | - Simon Specklin
- UMR 1023 IMIV
- Service Hospitalier Frédéric Joliot (SHFJ)
- CEA, Inserm
- Université Paris Sud, CNRS
- Université Paris-Saclay
| |
Collapse
|
26
|
Gounder M, Schöffski P, Villalobos V, Cote G, Chugh R, Chen TW, Jahan T, Loggers E, Italiano A, Gupta A, Agulnik M, Attia S, Jones R, van Tine B, Demetri G, Roche M, Sapir I, Daigle S, Clawson A, Stacchiotti S. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy299.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
27
|
Stacchiotti S, Blay JY, Jones R, Demetri G, Mir O, Italiano A, Thomas D, Chen TW, Schöffski P, Gil T, Jahan T, Cote G, Ratan R, Attia S, Roche M, Daigle S, Sapir I, Clawson A, Gounder M. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy299.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Daigle S, Stacchiotti S, Schöffski P, Villalobos V, Cote G, Chugh R, Chen TW, Jahan T, Loggers E, Italiano A, Gupta A, Agulnik M, Attia S, Jones R, van Tine B, Demetri G, Clawson A, Roche M, Blakemore S, Gounder M. Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy304] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Roche M, Mukadam N, Adelman S, Livingston G. 72THE IDEMCARE - IMPROVING DEMENTIA CARE IN BLACK AFRICAN AND CARIBBEAN GROUPS STUDY: A FEASIBILITY CLUSTER RANDOMISED CONTROLLED TRIAL. Age Ageing 2018. [DOI: 10.1093/ageing/afy118.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Roche
- UCL Division of Psychiatry, 6th Floor Maple House, 149 Tottenham Court Road, London
| | - N Mukadam
- UCL Division of Psychiatry, 6th Floor Maple House, 149 Tottenham Court Road, London
| | - S Adelman
- UCL Division of Psychiatry, 6th Floor Maple House, 149 Tottenham Court Road, London
| | - G Livingston
- UCL Division of Psychiatry, 6th Floor Maple House, 149 Tottenham Court Road, London
| |
Collapse
|
30
|
Lossio-Ventura JA, Bian J, Jonquet C, Roche M, Teisseire M. A novel framework for biomedical entity sense induction. J Biomed Inform 2018; 84:31-41. [PMID: 29935347 DOI: 10.1016/j.jbi.2018.06.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 05/08/2018] [Accepted: 06/12/2018] [Indexed: 11/28/2022]
Abstract
BACKGROUND Rapid advancements in biomedical research have accelerated the number of relevant electronic documents published online, ranging from scholarly articles to news, blogs, and user-generated social media content. Nevertheless, the vast amount of this information is poorly organized, making it difficult to navigate. Emerging technologies such as ontologies and knowledge bases (KBs) could help organize and track the information associated with biomedical research developments. A major challenge in the automatic construction of ontologies and KBs is the identification of words with its respective sense(s) from a free-text corpus. Word-sense induction (WSI) is a task to automatically induce the different senses of a target word in the different contexts. In the last two decades, there have been several efforts on WSI. However, few methods are effective in biomedicine and life sciences. METHODS We developed a framework for biomedical entity sense induction using a mixture of natural language processing, supervised, and unsupervised learning methods with promising results. It is composed of three main steps: (1) a polysemy detection method to determine if a biomedical entity has many possible meanings; (2) a clustering quality index-based approach to predict the number of senses for the biomedical entity; and (3) a method to induce the concept(s) (i.e., senses) of the biomedical entity in a given context. RESULTS To evaluate our framework, we used the well-known MSH WSD polysemic dataset that contains 203 annotated ambiguous biomedical entities, where each entity is linked to 2-5 concepts. Our polysemy detection method obtained an F-measure of 98%. Second, our approach for predicting the number of senses achieved an F-measure of 93%. Finally, we induced the concepts of the biomedical entities based on a clustering algorithm and then extracted the keywords of reach cluster to represent the concept. CONCLUSIONS We have developed a framework for biomedical entity sense induction with promising results. Our study results can benefit a number of downstream applications, for example, help to resolve concept ambiguities when building Semantic Web KBs from biomedical text.
Collapse
Affiliation(s)
| | - J Bian
- College of Medicine, University of Florida, USA.
| | - C Jonquet
- University of Montpellier, LIRMM, CNRS, Montpellier, France.
| | - M Roche
- Cirad, TETIS, Montpellier, France; TETIS, Univ. Montpellier, APT, Cirad, Cnrs, Irstea, Montpellier, France.
| | | |
Collapse
|
31
|
Motta C, Conan F, Roche M, Thao Chan M. Lymphocyte membrane fluidity in peripheral vascular disease patients after treatment with pentoxifylline. Clin Hemorheol Microcirc 2018. [DOI: 10.3233/ch-1989-9105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- C. Motta
- Laboratoire de Biochemie - Hôtel Dieu - Clermont-Ferrand, France
| | - F. Conan
- Laboratoire de Biochemie - Hôtel Dieu - Clermont-Ferrand, France
| | | | - M. Thao Chan
- Laboratoire d’Hémorhéologie - Laboratoires Hoechst, 1 terrasse Bellini, 92080 Paris la Défense, France
| |
Collapse
|
32
|
Hossler C, Newell J, Roche M, Warrick J, Phaeton R, Kesterson J. HER2 and p95HER2 protein expression varies in primary versus metastatic serous endometrial cancer tumors. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
33
|
Roche M, Ozdemir B, Lane T, Uzzaman M, Sinha S. The Use of 'Failure-To-Rescue' ('FTR') as a Quality Metric - Systematic Review of the Literature and Reporting Recommendations. Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Roche M, Tumpach C, Symons J, Cameron P, Churchill M, Deeks S, Gorry P, Lewin S. 31 High prevalence of CXCR4-using virus and low clonal expansion in infected naïve and central memory CD4+ T cells in individuals on ART. J Virus Erad 2017. [DOI: 10.1016/s2055-6640(20)30736-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
35
|
Bradley DJ, McVay GL, Buckwalter CQ, Frischat GH, Veal BW, Lam DJ, Paulikas AP, Karim DP, Rosholt JN, Myers MN, Graff KA, Giddings JC, Relyea JF, Karim DP, Georgopoulos P, Knapp GS, Beitz JV, Hessler JP, Ruby SL, Helmke PA, Fung PC, Bird GW, Mclntyre NS, Sanipelli GG, Lopata VJ, Zielinski RA, Waltz WR, Godfrey WL, Williams AK, Hoovler GS, Neil Baldwin M, Eng RL, Welfare FG, Emanuel G, Roche M, Morin J, Musart R, Pierre B. Authors. NUCL TECHNOL 2017. [DOI: 10.13182/nt80-a32587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
36
|
Roche M, Morin J, Musart R, Pierre B. A New Neutron Detection Technique: Fissile Resistors. NUCL TECHNOL 2017. [DOI: 10.13182/nt80-a32606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Roche
- Commissariat à l’Energie Atomique, Centre d’Etudes de Valduc, Boîte Postale 14, 21120 Is sur Tille, France
| | - J. Morin
- Commissariat à l’Energie Atomique, Centre d’Etudes de Valduc, Boîte Postale 14, 21120 Is sur Tille, France
| | - R. Musart
- Commissariat à l’Energie Atomique, Centre d’Etudes de Valduc, Boîte Postale 14, 21120 Is sur Tille, France
| | - B. Pierre
- Commissariat à l’Energie Atomique, Centre d’Etudes de Valduc, Boîte Postale 14, 21120 Is sur Tille, France
| |
Collapse
|
37
|
Yahiaoui N, Roche M, Aissaoui-Hoffmann N, Keita BA, Mallaret M. Intravenous methylprednisolone induced acute pancreatitis. Eur J Clin Pharmacol 2017; 73:645-646. [DOI: 10.1007/s00228-017-2207-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 01/19/2017] [Indexed: 10/20/2022]
|
38
|
Affiliation(s)
- M. Roche
- School of People, Environment and Planning, Massey University, Palmerston North, New Zealand
| |
Collapse
|
39
|
Dyall SC, Mandhair HK, Fincham REA, Kerr DM, Roche M, Molina-Holgado F. Distinctive effects of eicosapentaenoic and docosahexaenoic acids in regulating neural stem cell fate are mediated via endocannabinoid signalling pathways. Neuropharmacology 2016; 107:387-395. [PMID: 27044662 DOI: 10.1016/j.neuropharm.2016.03.055] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Revised: 03/30/2016] [Accepted: 03/31/2016] [Indexed: 11/29/2022]
Abstract
Emerging evidence suggests a complex interplay between the endocannabinoid system, omega-3 fatty acids and the immune system in the promotion of brain self-repair. However, it is unknown if all omega-3 fatty acids elicit similar effects on adult neurogenesis and if such effects are mediated or regulated by interactions with the endocannabinoid system. This study investigated the effects of DHA and EPA on neural stem cell (NSC) fate and the role of the endocannabinoid signalling pathways in these effects. EPA, but not DHA, significantly increased proliferation of NSCs compared to controls, an effect associated with enhanced levels of the endocannabinoid 2-arachidonylglycerol (2-AG) and p-p38 MAPK, effects attenuated by pre-treatment with CB1 (AM251) or CB2 (AM630) receptor antagonists. Furthermore, in NSCs derived from IL-1β deficient mice, EPA significantly decreased proliferation and p-p38 MAPK levels compared to controls, suggesting a key role for IL-1β signalling in the effects observed. Although DHA similarly increased 2-AG levels in wild-type NSCs, there was no concomitant increase in proliferation or p-p38 MAPK activity. In addition, in NSCs from IL-1β deficient mice, DHA significantly increased proliferation without effects on p-P38 MAPK, suggesting effects of DHA are mediated via alternative signalling pathways. These results provide crucial new insights into the divergent effects of EPA and DHA in regulating NSC proliferation and the pathways involved, and highlight the therapeutic potential of their interplay with endocannabinoid signalling in brain repair.
Collapse
Affiliation(s)
- S C Dyall
- Department of Life Sciences, University of Roehampton, Whitelands College, London, UK; Faculty of Health and Social Sciences, Bournemouth University, Dorset, UK.
| | - H K Mandhair
- Department of Life Sciences, University of Roehampton, Whitelands College, London, UK
| | - R E A Fincham
- Department of Life Sciences, University of Roehampton, Whitelands College, London, UK
| | - D M Kerr
- Physiology, School of Medicine, National University of Ireland, Galway, Ireland; Pharmacology and Therapeutics, School of Medicine, National University of Ireland, Galway, Ireland; NCBES Centre for Pain Research and Neuroscience Centre, National University of Ireland, Galway, Ireland
| | - M Roche
- Physiology, School of Medicine, National University of Ireland, Galway, Ireland; NCBES Centre for Pain Research and Neuroscience Centre, National University of Ireland, Galway, Ireland
| | - F Molina-Holgado
- Department of Life Sciences, University of Roehampton, Whitelands College, London, UK
| |
Collapse
|
40
|
Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, Sant M, Hackl M, Zielonke N, Oberaigner W, Van Eycken E, Henau K, Valerianova Z, Dimitrova N, Sekerija M, Zvolský M, Dušek L, Storm H, Engholm G, Mägi M, Aareleid T, Malila N, Seppä K, Velten M, Troussard X, Bouvier V, Launoy G, Guizard A, Faivre J, M. Bouvier A, Arveux P, Maynadié M, Woronoff A, Robaszkiewicz M, Baldi I, Monnereau A, Tretarre B, Bossard N, Belot A, Colonna M, Molinié F, Bara S, Schvartz C, Lapôtre-Ledoux B, Grosclaude P, Meyer M, Stabenow R, Luttmann S, Eberle A, Brenner H, Nennecke A, Engel J, Schubert-Fritschle G, Kieschke J, Heidrich J, Holleczek B, Katalinic A, Jónasson J, Tryggvadóttir L, Comber H, Mazzoleni G, Bulatko A, Buzzoni C, Giacomin A, Sutera Sardo A, Mazzei A, Ferretti S, Crocetti E, Manneschi G, Gatta G, Sant M, Amash H, Amati C, Baili P, Berrino F, Bonfarnuzzo S, Botta L, Di Salvo F, Foschi R, Margutti C, Meneghini E, Minicozzi P, Trama A, Serraino D, Zucchetto A, De Angelis R, Caldora M, Capocaccia R, Carrani E, Francisci S, Mallone S, Pierannunzio D, Roazzi P, Rossi S, Santaquilani M, Tavilla A, Pannozzo F, Busco S, Bonelli L, Vercelli M, Gennaro V, Ricci P, Autelitano M, Randi G, Ponz De Leon M, Marchesi C, Cirilli C, Fusco M, Vitale M, Usala M, Traina A, Zarcone M, Vitale F, Cusimano R, Michiara M, Tumino R, Giorgi Rossi P, Vicentini M, Falcini F, Iannelli A, Sechi O, Cesaraccio R, Piffer S, Madeddu A, Tisano F, Maspero S, Fanetti A, Zanetti R, Rosso S, Candela P, Scuderi T, Stracci F, Rocca A, Tagliabue G, Contiero P, Dei Tos A, Tognazzo S, Pildava S, Smailyte G, Calleja N, Micallef R, Johannesen T, Rachtan J, Gózdz S, Mezyk R, Blaszczyk J, Kepska K, Bielska-Lasota M, Forjaz de Lacerda G, Bento M, Antunes L, Miranda A, Mayer-da-Silva A, Nicula F, Coza D, Safaei Diba C, Primic-Zakelj M, Almar E, Mateos A, Errezola M, Larrañaga N, Torrella-Ramos A, Díaz García J, Marcos-Navarro A, Marcos-Gragera R, Vilardell L, Sanchez M, Molina E, Navarro C, Chirlaque M, Moreno-Iribas C, Ardanaz E, Galceran J, Carulla M, Lambe M, Khan S, Mousavi M, Bouchardy C, Usel M, Ess S, Frick H, Lorez M, Ess S, Herrmann C, Bordoni A, Spitale A, Konzelmann I, Visser O, Aben K, Coleman M, Allemani C, Rachet B, Verne J, Easey N, Lawrence G, Moran T, Rashbass J, Roche M, Wilkinson J, Gavin A, Fitzpatrick D, Brewster D, Huws D, White C, Otter R. Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. Eur J Cancer 2015; 51:2217-2230. [DOI: 10.1016/j.ejca.2015.07.028] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2015] [Revised: 07/02/2015] [Accepted: 07/20/2015] [Indexed: 12/22/2022]
|
41
|
De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, Visser O, Maynadié M, Marcos-Gragera R, Troussard X, Agius D, Roazzi P, Meneghini E, Monnereau A, Hackl M, Zielonke N, Oberaigner W, Van Eycken E, Henau K, Valerianova Z, Dimitrova N, Sekerija M, Zvolský M, Dušek L, Storm H, Engholm G, Mägi M, Aareleid T, Malila N, Seppä K, Velten M, Troussard X, Bouvier V, Launoy G, Guizard A, Faivre J, Bouvier A, Arveux P, Maynadié M, Woronoff A, Robaszkiewicz M, Baldi I, Monnereau A, Tretarre B, Bossard N, Belot A, Colonna M, Molinié F, Bara S, Schvartz C, Lapôtre-Ledoux B, Grosclaude P, Meyer M, Stabenow R, Luttmann S, Eberle A, Brenner H, Nennecke A, Engel J, Schubert-Fritschle G, Kieschke J, Heidrich J, Holleczek B, Katalinic A, Jónasson J, Tryggvadóttir L, Comber H, Mazzoleni G, Bulatko A, Buzzoni C, Giacomin A, Sutera Sardo A, Mancuso P, Ferretti S, Crocetti E, Caldarella A, Gatta G, Sant M, Amash H, Amati C, Baili P, Berrino F, Bonfarnuzzo S, Botta L, Di Salvo F, Foschi R, Margutti C, Meneghini E, Minicozzi P, Trama A, Serraino D, Dal Maso L, De Angelis R, Caldora M, Capocaccia R, Carrani E, Francisci S, Mallone S, Pierannunzio D, Roazzi P, Rossi S, Santaquilani M, Tavilla A, Pannozzo F, Busco S, Bonelli L, Vercelli M, Gennaro V, Ricci P, Autelitano M, Randi G, Ponz De Leon M, Marchesi C, Cirilli C, Fusco M, Vitale M, Usala M, Traina A, Staiti R, Vitale F, Ravazzolo B, Michiara M, Tumino R, Giorgi Rossi P, Di Felice E, Falcini F, Iannelli A, Sechi O, Cesaraccio R, Piffer S, Madeddu A, Tisano F, Maspero S, Fanetti A, Zanetti R, Rosso S, Candela P, Scuderi T, Stracci F, Bianconi F, Tagliabue G, Contiero P, Dei Tos A, Guzzinati S, Pildava S, Smailyte G, Calleja N, Agius D, Johannesen T, Rachtan J, Gózdz S, Mezyk R, Blaszczyk J, Bebenek M, Bielska-Lasota M, Forjaz de Lacerda G, Bento M, Castro C, Miranda A, Mayer-da-Silva A, Nicula F, Coza D, Safaei Diba C, Primic-Zakelj M, Almar E, Ramírez C, Errezola M, Bidaurrazaga J, Torrella-Ramos A, Díaz García J, Jimenez-Chillaron R, Marcos-Gragera R, Izquierdo Font A, Sanchez M, Chang D, Navarro C, Chirlaque M, Moreno-Iribas C, Ardanaz E, Galceran J, Carulla M, Lambe M, Khan S, Mousavi M, Bouchardy C, Usel M, Ess S, Frick H, Lorez M, Ess S, Herrmann C, Bordoni A, Spitale A, Konzelmann I, Visser O, Lemmens V, Coleman M, Allemani C, Rachet B, Verne J, Easey N, Lawrence G, Moran T, Rashbass J, Roche M, Wilkinson J, Gavin A, Donnelly C, Brewster D, Huws D, White C, Otter R. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study. Eur J Cancer 2015; 51:2254-2268. [DOI: 10.1016/j.ejca.2015.08.003] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 08/06/2015] [Accepted: 08/11/2015] [Indexed: 12/28/2022]
|
42
|
Guallart J, García-Salinas P, Ahuir-Baraja AE, Guimerans M, Ellis JR, Roche M. Angular roughshark Oxynotus centrina (Squaliformes: Oxynotidae) in captivity feeding exclusively on elasmobranch eggs: an overlooked feeding niche or a matter of individual taste? J Fish Biol 2015; 87:1072-1079. [PMID: 26283180 DOI: 10.1111/jfb.12761] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/09/2015] [Accepted: 06/24/2015] [Indexed: 06/04/2023]
Abstract
A specimen of angular roughshark Oxynotus centrina has been kept successfully in captivity for the first time. Over a period of 24 months, the specimen preyed exclusively on the contents of elasmobranch egg cases, suggesting a specialized trophic niche.
Collapse
Affiliation(s)
- J Guallart
- Laboratorio de Biología Marina, Departamento de Zoología, Universitat de València, E-46100 Burjassot, Valencia, Spain
| | - P García-Salinas
- Laboratorio de Biología Marina, Departamento de Zoología, Universitat de València, E-46100 Burjassot, Valencia, Spain
| | - A E Ahuir-Baraja
- Unidad de Zoología Marina, Instituto Cavanilles de Biodiversidad y Biología Evolutiva, Parque Científico de la Universitat de València, c/ Catedrático José Beltrán, 2, E-46980 Paterna, Valencia, Spain
| | - M Guimerans
- Oceanogràfic, Ciudad de las Artes y las Ciencias de Valencia, c/ Eduardo Primo Yúfera (Científic), 1B, E-46013, Valencia, Spain
| | - J R Ellis
- Centre for Environment, Fisheries and Aquaculture Science (CEFAS), Lowestoft Laboratory, Pakefield Road, Lowestoft, Suffolk, NR33 0HT, U.K
| | - M Roche
- Oceanogràfic, Ciudad de las Artes y las Ciencias de Valencia, c/ Eduardo Primo Yúfera (Científic), 1B, E-46013, Valencia, Spain
| |
Collapse
|
43
|
Trama A, Foschi R, Larrañaga N, Sant M, Fuentes-Raspall R, Serraino D, Tavilla A, Van Eycken L, Nicolai N, Hackl M, Zielonke N, Oberaigner W, Van Eycken E, Henau K, Valerianova Z, Dimitrova N, Sekerija M, Zvolský M, Dušek L, Storm H, Engholm G, Mägi M, Aareleid T, Malila N, Seppä K, Velten M, Troussard X, Bouvier V, Launoy G, Guizard A, Faivre J, Bouvier A, Arveux P, Maynadié M, Woronoff A, Robaszkiewicz M, Baldi I, Monnereau A, Tretarre B, Bossard N, Belot A, Colonna M, Molinié F, Bara S, Schvartz C, Lapôtre-Ledoux B, Grosclaude P, Meyer M, Stabenow R, Luttmann S, Eberle A, Brenner H, Nennecke A, Engel J, Schubert-Fritschle G, Kieschke J, Heidrich J, Holleczek B, Katalinic A, Jónasson J, Tryggvadóttir L, Comber H, Mazzoleni G, Bulatko A, Buzzoni C, Giacomin A, Sutera Sardo A, Mancuso P, Ferretti S, Crocetti E, Caldarella A, Gatta G, Sant M, Amash H, Amati C, Baili P, Berrino F, Bonfarnuzzo S, Botta L, Di Salvo F, Foschi R, Margutti C, Meneghini E, Minicozzi P, Trama A, Serraino D, Dal Maso L, De Angelis R, Caldora M, Capocaccia R, Carrani E, Francisci S, Mallone S, Pierannunzio D, Roazzi P, Rossi S, Santaquilani M, Tavilla A, Pannozzo F, Busco S, Bonelli L, Vercelli M, Gennaro V, Ricci P, Autelitano M, Randi G, Ponz De Leon M, Marchesi C, Cirilli C, Fusco M, F. Vitale M, Usala M, Traina A, Staiti R, Vitale F, Ravazzolo B, Michiara M, Tumino R, Giorgi Rossi P, Di Felice E, Falcini F, Iannelli A, Sechi O, Cesaraccio R, Piffer S, Madeddu A, Tisano F, Maspero S, Fanetti A, Zanetti R, Rosso S, Candela P, Scuderi T, Stracci F, Bianconi F, Tagliabue G, Contiero P, Dei Tos A, Guzzinati S, Pildava S, Smailyte G, Calleja N, Agius D, Johannesen T, Rachtan J, Gózdz S, Mezyk R, Blaszczyk J, Bebenek M, Bielska-Lasota M, Forjaz de Lacerda G, Bento M, Castro C, Miranda A, Mayer-da-Silva A, Nicula F, Coza D, Safaei Diba C, Primic-Zakelj M, Almar E, Ramírez C, Errezola M, Bidaurrazaga J, Torrella-Ramos A, Díaz García J, Jimenez-Chillaron R, Marcos-Gragera R, Izquierdo Font A, J. Sanchez M, Chang D, Navarro C, Chirlaque M, Moreno-Iribas C, Ardanaz E, Galceran J, Carulla M, Lambe M, Khan S, Mousavi M, Bouchardy C, Usel M, M. Ess S, Frick H, Lorez M, Ess S, Herrmann C, Bordoni A, Spitale A, Konzelmann I, Visser O, Verhoeven R, Coleman M, Allemani C, Rachet B, Verne J, Easey N, Lawrence G, Moran T, Rashbass J, Roche M, Wilkinson J, Gavin A, Donnelly C, Brewster D, Huws D, White C, Otter R. Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: Results from the EUROCARE-5 study. Eur J Cancer 2015; 51:2206-2216. [DOI: 10.1016/j.ejca.2015.07.027] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 07/09/2015] [Accepted: 07/20/2015] [Indexed: 11/26/2022]
|
44
|
Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, Pierannunzio D, Sant M, Trama A, Faivre J, Zielonke N, Oberaigner W, Van Eycken E, Henau K, Valerianova Z, Dimitrova N, Sekerija M, Zvolský M, Dušek L, Storm H, Engholm G, Mägi M, Aareleid T, Malila N, Seppä K, Velten M, Troussard X, Bouvier V, Launoy G, Guizard A, Faivre J, Bouvier A, Arveux P, Maynadié M, Woronoff A, Robaszkiewicz M, Baldi I, Monnereau A, Tretarre B, Bossard N, Belot A, Colonna M, Molinié F, Bara S, Schvartz C, Lapôtre-Ledoux B, Grosclaude P, Meyer M, Stabenow R, Luttmann S, Eberle A, Brenner H, Nennecke A, Engel J, Schubert-Fritschle G, Kieschke J, Heidrich J, Holleczek B, Katalinic A, Jónasson J, Tryggvadóttir L, Comber H, Mazzoleni G, Bulatko A, Buzzoni C, Giacomin A, Sutera Sardo A, Mancuso P, Ferretti S, Crocetti E, Caldarella A, Gatta G, Sant M, Amash H, Amati C, Baili P, Berrino F, Bonfarnuzzo S, Botta L, Di Salvo F, Foschi R, Margutti C, Meneghini E, Minicozzi P, Trama A, Serraino D, Dal Maso L, De Angelis R, Caldora M, Capocaccia R, Carrani E, Francisci S, Mallone S, Pierannunzio D, Roazzi P, Rossi S, Santaquilani M, Tavilla A, Pannozzo F, Busco S, Bonelli L, Vercelli M, Gennaro V, Ricci P, Autelitano M, Randi G, Ponz De Leon M, Marchesi C, Cirilli C, Fusco M, Vitale M, Usala M, Traina A, Staiti R, Vitale F, Ravazzolo B, Michiara M, Tumino R, Giorgi Rossi P, Di Felice E, Falcini F, Iannelli A, Sechi O, Cesaraccio R, Piffer S, Madeddu A, Tisano F, Maspero S, Fanetti A, Zanetti R, Rosso S, Candela P, Scuderi T, Stracci F, Bianconi F, Tagliabue G, Contiero P, Dei Tos A, Guzzinati S, Pildava S, Smailyte G, Calleja N, Agius D, Johannesen T, Rachtan J, Gózdz S, Mezyk R, Blaszczyk J, Bebenek M, Bielska-Lasota M, Forjaz de Lacerda G, Bento M, Castro C, Miranda A, Mayer-da-Silva A, Nicula F, Coza D, Safaei Diba C, Primic-Zakelj M, Almar E, Ramírez C, Errezola M, Bidaurrazaga J, Torrella-Ramos A, Díaz García J, Jimenez-Chillaron R, Marcos-Gragera R, Izquierdo Font A, Sanchez M, Chang D, Navarro C, Chirlaque M, Moreno-Iribas C, Ardanaz E, Galceran J, Carulla M, Lambe M, Khan S, Mousavi M, Bouchardy C, Usel M, Ess S, Frick H, Lorez M, Ess S, Herrmann C, Bordoni A, Spitale A, Konzelmann I, Visser O, van der Geest L, Otter R, Coleman M, Allemani C, Rachet B, Verne J, Easey N, Lawrence G, Moran T, Rashbass J, Roche M, Wilkinson J, Gavin A, Donnelly C, Brewster D, Huws D, White C. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5. Eur J Cancer 2015; 51:2169-2178. [PMID: 26421820 DOI: 10.1016/j.ejca.2015.07.034] [Citation(s) in RCA: 107] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Revised: 07/10/2015] [Accepted: 07/20/2015] [Indexed: 12/14/2022]
Abstract
BACKGROUND The EUROCARE study collects and analyses survival data from population-based cancer registries (CRs) in Europe in order to provide data on between-country differences in survival and time trends in survival. METHODS This study analyses data on liver cancer, gallbladder and extrahepatic biliary tract cancers ("biliary tract cancers"), and pancreatic cancer diagnosed in 2000-2007 from 88 CRs in 29 countries. Relative survival (RS) was estimated overall, by region, sex, age and period of diagnosis using the complete approach. Time trends in 5-year RS over 1999-2007 were also analysed using the period approach. RESULTS The prognosis of the studied cancers was poor. Age-standardised 5-year RS was 12% for liver cancer, 17% for biliary tract cancers and 7% for pancreatic cancer. There were some between-country differences in survival. In general, RS was low in Eastern Europe and high in Central and Southern Europe. For all sites, 5-year RS was similar in men and women and decreased with advancing age. No substantial changes in survival were reported for pancreatic cancer over the period 1999-2007. On average, there was a crude increase in 5-year RS of 3 percentage points between the periods 1999-2001 and 2005-2007 for liver cancer and biliary tract cancers. CONCLUSIONS The major changes in imaging techniques over the study period for the diagnosis of the three studied cancers did not result in an improvement in the prognosis of these cancers. In the near future, new innovative treatments might be the best way to improve the prognosis in these cancers.
Collapse
Affiliation(s)
- Côme Lepage
- Burgundy Cancer Registry, INSERM U866, Dijon, France; Department of Gastroenterology, University Hospital, Dijon, France; Burgundy University, Dijon, France.
| | | | - Monika Hackl
- Bundesanstalt statistical Osterreich, Vienna, Austria
| | - Valerie Lemmens
- Departement of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | - Esther Molina
- Escuela Andaluza de Salud Peblica, Insituto de Investigation biosanitaria, Hospitales Universitarios Universidad Granada, Spain
| | | | - Milena Sant
- Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
| | - Annalisa Trama
- Evaluative Epidemiology Unit, Department of Preventive and Predictive medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
| | - Jean Faivre
- Burgundy Cancer Registry, INSERM U866, Dijon, France; Department of Gastroenterology, University Hospital, Dijon, France; Burgundy University, Dijon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Rizzi P, Guillier D, See LA, Roche M, Zwetyenga N. [Pathomimia and plastic surgery, a case report]. ANN CHIR PLAST ESTH 2015; 60:518-21. [PMID: 26362995 DOI: 10.1016/j.anplas.2015.08.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 08/11/2015] [Indexed: 10/23/2022]
Abstract
Pathomimia is defined as a dummy pathology self-induced deliberately and is neither associated with mental confusion nor disturbance of consciousness. This article reports a case of pathomimia in plastic surgery. One of our patients had intentionally injected physiological saline solution into her breast implants in order to increase their volume. Implants removal was necessary because of severe local inflammatory signs. Psychiatric assessment revealed body dysmorphic disorder (BDD) developed on an hysterical personality, which explained the self-induced injuries. This nosologic entity must be promptly identified because it's diagnosis remains problematic and a multidisciplinary medical management is essential.
Collapse
Affiliation(s)
- P Rizzi
- Service de chirurgie plastique, reconstructrice et esthétique, chirurgie de la main, chirurgie maxillo-faciale, CHU Bocage Central, 14, rue Gaffarel, 21079 Dijon cedex, France.
| | - D Guillier
- Service de chirurgie plastique, reconstructrice et esthétique, chirurgie de la main, chirurgie maxillo-faciale, CHU Bocage Central, 14, rue Gaffarel, 21079 Dijon cedex, France
| | - L A See
- Service de chirurgie plastique, reconstructrice et esthétique, chirurgie de la main, chirurgie maxillo-faciale, CHU Bocage Central, 14, rue Gaffarel, 21079 Dijon cedex, France
| | - M Roche
- Service de chirurgie plastique, reconstructrice et esthétique, chirurgie de la main, chirurgie maxillo-faciale, CHU Bocage Central, 14, rue Gaffarel, 21079 Dijon cedex, France
| | - N Zwetyenga
- Service de chirurgie plastique, reconstructrice et esthétique, chirurgie de la main, chirurgie maxillo-faciale, CHU Bocage Central, 14, rue Gaffarel, 21079 Dijon cedex, France
| |
Collapse
|
46
|
Cashin K, Gray LR, Harvey KL, Perez-Bercoff D, Lee GQ, Sterjovski J, Roche M, Demarest JK, Drummond F, Harrigan R, Churchill MJ, Gorry PR. 009.3 Relibale genotypic tropism tests for the major hiv-1 subtypes. Br J Vener Dis 2015. [DOI: 10.1136/sextrans-2015-052270.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Motta C, Roche M. Platelet membrane fluidity and order modification after the binding of the anti-Zwa antibody. Fluorescence polarization study. Curr Stud Hematol Blood Transfus 2015:64-8. [PMID: 3366006 DOI: 10.1159/000415425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- C Motta
- Laboratoire de Biochimie, Hôtel-Dieu, Clermont-Ferrand, France
| | | |
Collapse
|
48
|
Okine BN, Rea K, Olango WM, Price J, Herdman S, Madasu MK, Roche M, Finn DP. A role for PPARα in the medial prefrontal cortex in formalin-evoked nociceptive responding in rats. Br J Pharmacol 2014; 171:1462-71. [PMID: 24303983 DOI: 10.1111/bph.12540] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2013] [Revised: 10/02/2013] [Accepted: 10/27/2013] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND AND PURPOSE The nuclear hormone receptor, PPARα, and its endogenous ligands, are involved in pain modulation. PPARα is expressed in the medial prefrontal cortex (mPFC), a key brain region involved in both the cognitive-affective component of pain and in descending modulation of pain. However, the role of PPARα in the mPFC in pain responding has not been investigated. Here, we investigated the effects of pharmacological modulation of PPARα in the rat mPFC on formalin-evoked nociceptive behaviour and the impact of formalin-induced nociception on components of PPARα signalling in the mPFC. EXPERIMENTAL APPROACH The effects of intra-mPFC microinjection of a PPARα agonist (GW7647) or a PPARα antagonist (GW6471) on formalin-evoked nociceptive behaviour in rats were studied. Quantitative real-time PCR and LC-MS/MS were used to study the effects of intraplantar injection of formalin on PPARα mRNA expression and levels of endogenous ligands, respectively, in the mPFC. KEY RESULTS Intra-mPFC administration of GW6471, but not GW7647, resulted in delayed onset of the early second phase of formalin-evoked nociceptive behaviour. Furthermore, formalin-evoked nociceptive behaviour was associated with significant reductions in mPFC levels of endogenous PPARα ligands (N-palmitoylethanolamide and N-oleoylethanolamide) and a 70% reduction in PPARα mRNA but not protein expression. CONCLUSIONS AND IMPLICATIONS These data suggest that endogenous ligands may act at PPARα in the mPFC to play a facilitatory/permissive role in second phase formalin-evoked nociceptive behaviour in rats. LINKED ARTICLES This article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-6.
Collapse
Affiliation(s)
- B N Okine
- Pharmacology and Therapeutics, School of Medicine, National University of Ireland Galway, Galway, Ireland; Galway Neuroscience Centre and Centre for Pain Research, NCBES, National University of Ireland Galway, Galway, Ireland
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Kerr DM, Harhen B, Okine BN, Egan LJ, Finn DP, Roche M. The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br J Pharmacol 2014; 169:808-19. [PMID: 23043675 DOI: 10.1111/j.1476-5381.2012.02237.x] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2012] [Revised: 08/31/2012] [Accepted: 09/05/2012] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND AND PURPOSE JZL184 is a selective inhibitor of monoacylglycerol lipase (MAGL), the enzyme that preferentially catabolizes the endocannabinoid 2-arachidonoyl glycerol (2-AG). Here, we have studied the effects of JZL184 on inflammatory cytokines in the brain and plasma following an acute immune challenge and the underlying receptor and molecular mechanisms involved. EXPERIMENTAL APPROACH JZL184 and/or the CB₁ receptor antagonist, AM251 or the CB₂ receptor antagonist, AM630 were administered to rats 30 min before lipopolysaccharide (LPS). 2 h later cytokine expression and levels, MAGL activity, 2-AG, arachidonic acid and prostaglandin levels were measured in the frontal cortex, plasma and spleen. KEY RESULTS JZL184 attenuated LPS-induced increases in IL-1β, IL-6, TNF-α and IL-10 but not the expression of the inhibitor of NFkB (IκBα) in rat frontal cortex. AM251 attenuated JZL184-induced decreases in frontal cortical IL-1β expression. Although arachidonic acid levels in the frontal cortex were reduced in JZL184-treated rats, MAGL activity, 2-AG, PGE₂ and PGD₂ were unchanged. In comparison, MAGL activity was inhibited and 2-AG levels enhanced in the spleen following JZL184. In plasma, LPS-induced increases in TNF-α and IL-10 levels were attenuated by JZL184, an effect partially blocked by AM251. In addition, AM630 blocked LPS-induced increases in plasma IL-1β in the presence, but not absence, of JZL184. CONCLUSION AND IMPLICATIONS Inhibition of peripheral MAGL in rats by JZL184 suppressed LPS-induced circulating cytokines that in turn may modulate central cytokine expression. The data provide further evidence for the endocannabinoid system as a therapeutic target in treatment of central and peripheral inflammatory disorders.
Collapse
Affiliation(s)
- D M Kerr
- Physiology, School of Medicine, National University of Ireland, Galway, Ireland
| | | | | | | | | | | |
Collapse
|
50
|
Radosevic-Robin NZ, Abrial C, Dauplat MM, Kwiatkowski F, Cayre A, Maury F, Roche M, Chalabi N, Mouret-Reynier MA, Penault-Llorca F, Nabholtz JM. Abstract P5-08-07: HER3, MET and immune pathways play important roles in the resistance of triple negative breast cancer (TNBC) after neoadjuvant anti-EGFR (panitumumab) combined with FEC 100. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Our group has previously reported (SABCS 2012, abstract 1081) a 2-fold higher pathologic complete response (pCR) rate in TNBC treated with panitumumab+FEC100 (47%) than with the standard therapy alone. However, in a half of the patients (pts) a residual tumor (RT) was detected. Having in mind the detrimental impact of resistant TNBC on patient outcome, we have investigated the tumor tissue factors that might have been important in development of resistance to this treatment.
Methods: 40 TNBC pts, treated with 8 cycles the anti-EGFR antibody panitumumab combined with FEC 100 for the first 4 and with docetaxel only for the last 4 cycles, were eligible. All pts underwent breast surgery after the neoadjuvant chemotherapy (NACT) completion. Formalin-fixed, paraffin-embedded tumor samples were collected before and after NACT for biomarker analysis. EGFR, HER3, IGF-1R, MET and the number of FOXP3+ or CD8+ tumor-infiltrating lymphocytes (TIL) were evaluated by immunohistochemistry (IHC). Expression of the kinases was graded semi-quantitatively (histoscores).
Results: Out of 40 treated pts, 21 demonstrated a RT (53%, according to the Chevallier classification, PMID 8338056). The IHC data were available for 17 pts. Since high EGFR expression was important for pCR achievement in this study (SABC 2012), we first investigated the expressions of EGFR, HER3 and MET in the RT. The results are presented in Table 1.
Table 1post-NACT RTn = 17EGFR down or flatEGFR up143HER3 upHER3 flatHER3 upHER3 flat8512MET upMET down or flatMET upMET down or flatMET upMET down or flatMET upMET down or flat17220120
Overall, among the 9 cases (cs) with increased post-NACT HER3 expression (HER3 up), only 1 had increased MET (MET up), while among the 7 cs with no change in HER3 post-CTNA (HER3 flat), 4 had MET expression increased.
Interestingly, although the pre-NACT IGF-1R expression was a strong predictor of pCR (p = 0.028, SABCS 2012), no significant changes in this kinase expression were observed in the RT, compared to the pre-NACT levels. Most RT had low IGF-1R scores (<100). The only 2 RT in which IGF-1R was increased post-CTNA were small groups of tumor cells either in breast or in the nodes, heavily surrounded by lymphocytes.
The density of TIL post-NACT correlated principally with the% of tumor mass (TM) reduction. Among the 7 pts with average reduction of 20%, there was only 1 cs with a good InSitu Immune Response (ISIR: dense TIL, with CD8+/FOXP3+ > 1.2). On the contrary, among the 9 pts with average TM reduction of 90%, 8 demonstrated a good ISIR.
Conclusion: The results indicate that HER3 and MET play significant roles in development of TNBC resistance to the anti-EGFR agents. Those molecules seem to drive 2 different resistance pathways in TNBC, as it has been shown in other malignancies. As several anti-HER3 or anti-MET drugs are nowadays available, we find very important investigating the expression of HER3 and MET in each TNBC pt pre- and post-NACT, in order to rapidly detect and combat the resistance. The ISIR-stimulating agents may bring an additional therapeutic benefit to those patients.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-08-07.
Collapse
Affiliation(s)
- NZ Radosevic-Robin
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - C Abrial
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - MM Dauplat
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - F Kwiatkowski
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - A Cayre
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - F Maury
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - M Roche
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - N Chalabi
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - MA Mouret-Reynier
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - F Penault-Llorca
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| | - JM Nabholtz
- Jean Perrin Comprehensive Cancer Center and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Sipath Unilabs, Clermont-Ferrand, France
| |
Collapse
|